2.7.4.6 Post-marketing Data
If the drug has already been marketed, all relevant post-marketing data available to the
applicant (published and unpublished, including periodic safety update reports if available)
should be summarised. The periodic safety update reports can be included in Module 5.
Details of the number of subjects estimated to have been exposed should be provided and
categorised, as appropriate, by indication, dosage, route, treatment duration, and geographic
location. The methodology used to estimate the number of subjects exposed should be
described. If estimates of the demographic details are available from any source, these should
be provided.
A tabulation of serious events reported after the drug is marketed should be provided,
including any potentially serious drug interactions.
Any post-marketing findings in subgroups should be described

